New hope for advanced breast cancer: experimental drug targets resistant tumors

NCT ID NCT07214662

Recruiting now Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 27 times

Summary

This study tests an experimental drug called GDC-0587, alone or with another drug (giredestrant), in people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has gotten worse after previous treatment. The goal is to find a safe dose and see if the drug can shrink tumors. About 136 adults will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cheng Kung University Hospital
RECRUITING

Tainan, 70403, Taiwan
National Taiwan University Hospital
RECRUITING

Taipei, Taipei City, 10002, Taiwan
START - Midwest - EDOS
RECRUITING

Grand Rapids, Michigan, 49546-7062, United States
START - San Antonio - EDOS
RECRUITING

San Antonio, Texas, 78229-3307, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER